Vmbook Online ordering

Aurios Inc

Auris Medical Holding AG, trading under the ticker symbol "EARS" on the NASDAQ Capital Market, is a clinical-stage company focused on developing therapeutics for inner ear disorders. However, it seems there is no longer a company listed under the symbol "AURZ" on any major U.S. stock exchange.

I assume you may have meant "EARS" instead of "AURZ". I can provide you with some general information about Auris Medical Holding AG (EARS) based on publicly available information as of the time of this response.

1. Company Overview:

Auris Medical Holding AG is a clinical-stage company dedicated to developing innovative therapeutics for inner ear disorders. The company's primary focus is on developing treatments for tinnitus and age-related hearing loss.

2. Key Products:

- AM-101: A drug candidate for the treatment of acute inner ear tinnitus.

- AM-111: A drug candidate for the treatment of inner ear hearing loss, particularly following extremely loud noise exposure or due to sudden sensorineural hearing loss.

3. Financial Status:

To provide specific information on the company's earnings, growth, and financials, I would need to access the most recent financial statements. However, as of the time of this response, the company's latest reported quarterly revenue was for Q3 2021, at -5.54 million CHF (Swiss Francs). It's important to review the company's financial statements and other financial resources for a comprehensive understanding of their financial health.

Keep in mind that the information provided above is based on publicly available information as of the time of this response. It's essential to consult the company's official website, financial statements, and other official resources for the most up-to-date and accurate information.